Smith+Nephew announces the premiere of its newly acquired CARTIHEAL AGILI-C Cartilage Repair Implant alongside the REGENETEN Bioinductive Implant at the AAOS Annual Meeting, demonstrating its leadership with products that enable biological healing for Sports Medicine. “As a leader in Sports Medicine, we are committed to bringing emerging technologies that address unmet clinical needs to our customers and their patients,” said Scott Schaffner, President Sports Medicine, Smith+Nephew. “Both REGENETEN and CARTIHEAL AGILI-C implants have the opportunity to set new benchmarks for standard of care across multiple joint repair indications and deliver better patient outcomes.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SNN:
- Smith+Nephew unveils expanded Sports Medicine portfolio to enable biological healing at AAOS 2024 Annual Meeting
- Smith & Nephew price target lowered to 1,450 GBp from 1,500 GBp at Berenberg
- Australia’s approach to musculoskeletal injury care and reimbursement demands rethink: Report
- Smith & Nephew announces results for its REGENETEN Bioinductive Implant
- New study confirms Smith+Nephew’s REGENETEN™ Bioinductive Implant reduces full-thickness rotator cuff re-tear rates¹ by 68%